Human MAPK1 (ERK2) Knockout A549 Cell Lysate
Western Blot of Human MAPK1 (ERK2) Knockout A549 Cell Lysate
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

Human MAPK1 (ERK2) Knockout A549 Cell Lysate

W09-K01-MU1
100 µg
WB, SDS-PAGE
Human
$425.00 /Per Item
Request a Quote
Bulk Orders
Availability: Ships next business day
Shipping info:

$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.

Background

ERK2 antibodies detect the ERK2 isoform. Mitogen activated protein kinase 1, also known as MAPK1, ERK, or ERK2, is an integral component of the MAP kinase cascade that regulates cell growth and differentiation. ERK1 and ERK2 are activated by MEK1 and MEK2 in the B-raf signaling pathway resulting in its translocation to the nucleus where it phosphorylates nuclear targets. Human ERK1 and ERK2 are 84% identical in sequence and share common functionality in cells.

Product Details

Human MAPK1 (ERK2) Knockout A549 Lysate - W09-K01-MU1
rabbit anti-ERK2 antibody, MAPK1, ERK 2, ERK-2, P42MAPK, PRKM1, PRKM2, MAPK 2, MAP kinase 2, Mitogen-activated protein kinase 2, p42-MAPK, MAP kinase isoform p42, Extracellular signal-regulated kinase 2, ERT1, MAP kinase 1, Mitogen-activated protein kinase 1
Human

Target Details

MAPK1  - View All MAPK1 Products
MAPK1 (ERK2) knockout A549 cells were grown in Dulbecco’s medium supplemented with 10% fetal bovine serum. Cells were washed with PBS and then incubated on ice in modified RIPA buffer to lyse the cells. Protein integrity was ensured using a cocktail of protease inhibitors with broad specificity for the inhibition of aspartic, cysteine, and serine proteases as well as aminopeptidases (0.1 mM AEBSF HCl, 0.08 µM Aprotinin, 5 µM Bestatin, 1.5 µM E-64, 2 µM Leupeptin Hemisulfate, 1 µM Pepstatin A). Phosphatase inhibitors 1 mM NaF and 1 mM Na3VO4 were also added. Cell debris was removed by centrifugation. Protein concentration was determined by BCA using a commercially available kit. Protein concentration was adjusted to 2 mg/ml with modified 1X RIPA buffer. MAPK1 (ERK2) knockout A549 Clone 15 contains knockout deletions on all three copies of the MAPK1 (ERK2) gene in A549 cells. Each copy contains the same 104bp deletion induced by CRISPR/Cas9. The deletion occurs in exon 2 and disrupts the sequence between amino acids 59 to 94. These mutations induce a frame-shift and result in early stop codons. Validated by Sanger sequencing and Western blot.
UniProtKB - P28482

Application Details

SDS-PAGE, WB
Human MAPK1 (ERK2) Knockout A549 Cell Lysate has been tested by SDS-PAGE and western blot and is suitable for use in Western blot, ELISA, Immunoprecipitation and ChIP. No detection of expected band at ~44kDa is observed in MAPK1 (ERK2) knockout A549 when compared with unmodified A549 cell lysates by Western blot.

Cell Line Data

Human A549 (lung epithelial carcinoma)
Whole Cell Lysate
Not Stimulated
Tissue Culture
None (Control)

Formulation

Liquid (sterile filtered)
2.0 mg/mL by BCA assay
1X RIPA Buffer with HALT Protease and Phosphatase Inhibitors
None
None

Shipping & Handling

Dry Ice
Store vial at -70° C or COLDER. For extended storage, aliquot contents to minimize freeze/thaw cycles.
Expiration date is one (1) year from date of receipt.

Invalid lot number

If you need help finding your CoA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Related Resources

Melanoma Mutations

Articles
View Article

Rockland Introduces Melanoma Cell Lines

Videos
Watch Video

Tips for Culturing Human Melanoma Cell Lines

Technical Tips
View Technical Tip